CNS vs XENE: Which Is the Better Buy in 2026?

Last updated November 2026

Short answer

CNS (Cohen & Steers) and XENE (Xenon Pharmaceuticals) share investment themes but are different businesses. If you believe in growth, XENE fits: analysts expect its revenue to rise 2987% next year, against 1% for CNS. If you believe in profit, CNS fits: it is expected to make money next year (18.42x forward earnings), while XENE is still expected to post a loss.

CNS vs XENE: the tie-breaker metrics

Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

MetricCNSXENEWhat it tells you
Market cap$3.34B$3.66BSize. The larger name is the incumbent; the smaller has more room to grow and more to prove.
Forward P/E18.42-7.97Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up.
Beta1.180.08Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through.
Price vs 52-week range23% of range10% of rangeWhere today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why.
Price / book5.503.19How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price.

Before you buy: how CNS and XENE affect your concentration

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. CNS and XENE share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined CNS and XENE exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

What does Cohen & Steers (CNS) do?

Cohen & Steers is a global investment manager founded in 1986 that specializes in real assets and alternative income, including listed real estate (REITs), infrastructure, preferred securities, and multi-strategy real assets. It organized the first US real estate securities mutual fund and remains one of the largest managers of REIT securities in the world, with roughly two-thirds of assets in listed real estate. The firm earns management fees on the assets it runs across open-end funds, closed-end funds, institutional accounts, and newer vehicles like its non-traded REIT (CNSREIT), which in October 2026 bought the Manchester Village Shopping Center in Rock Hill, South Carolina and in November joined DLC to buy the West Street Shopping Center in Keene, New Hampshire.

Full CNS guide

What does Xenon Pharmaceuticals (XENE) do?

Xenon Pharmaceuticals is a Burnaby, Canada based, US-listed neuroscience biotech developing treatments for epilepsy and neuropsychiatric conditions. Its lead asset is azetukalner (formerly XEN1101), a potent KV7 potassium channel opener that, if approved, would be the only channel opener of its kind among antiseizure medications. The company is running a broad Phase 3 program spanning focal onset seizures, primary generalized tonic-clonic seizures, and neuropsychiatric indications including major depressive disorder and bipolar depression.

Full XENE guide

CNS vs XENE: how do they differ?

Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.

  • CNS drivers: Interest rates and real assets; Return to organic growth.
  • XENE drivers: Azetukalner FDA filing and launch; Pipeline breadth beyond focal epilepsy.

Which fits which kind of investor

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: CNS revenue is almost entirely tied to AUM, so equity or bond market drawdowns directly cut fees and earnings. For XENE, xenon has no approved product and no meaningful revenue, so the entire valuation rests on azetukalner clearing FDA review and selling once launched.

CNS or XENE: which should you pick?

If the story you believe is CNS's (Interest rates and real assets), CNS is the more direct way to own it; if it is XENE's (Azetukalner FDA filing and launch), XENE is. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the CNS and XENE guides.

CNS vs XENE: the full fundamentals

CNS. As of November 20, 2026, CNS trades at about 20 times trailing and 18.5 times forward earnings with a dividend yield near 4.1%, cheaper than in October after a further slide toward its 52-week low of about $58.39. AUM actually rose in October on market gains, so the gap between a recovering asset base and a falling share price is the current debate, alongside softer flows. The three analysts in the digest hold a mean target near $66.67 with a hold rating, close to the current price.

XENE. Xenon trades as a pre-revenue biotech, so traditional multiples like price-to-earnings do not apply, and the roughly $3.7 billion market cap (down from about $5 billion in June) reflects reduced expectations for azetukalner after the September psychiatry trial pause rather than any change in current financials. The company burns cash by design to fund Phase 3 trials and a commercial build, offset by a large cash position that management has said funds operations into 2029. Consensus calls for a 2026 loss of about $4.56 per share and a 2027 loss of about $4.67, and the 16 analysts tracked by Yahoo Finance had a mean price target near $72; valuation moves with clinical and regulatory milestones far more than with quarterly results.

Headline figures (approximate, November 2026): CNS shows revenue (ttm) ~$600M, +11% YoY in Q3 2026, revenue (q3 2026) ~$157.4M, adjusted eps (q3 2026) ~$0.89 vs ~$0.90 consensus, net income (ttm) / net margin ~$169M / ~28%; XENE shows market cap ~$3.7B, share price ~$37.23 (Nov 20, 2026), product revenue ~$0 (pre-commercial), net loss (q3 2026) ~$110M (EPS -$1.11 vs ~-$1.15 est.).

The bottom line: CNS vs XENE

CNS and XENE are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined CNS and XENE exposure against your real portfolio. It is not an investment adviser.

Wondering how CNS or XENE fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Cohen & Steers

Ask Walnut's AI anything about CNS and see how it fits what you own.

FAQ

What is the difference between CNS and XENE?

+

Cohen & Steers is a global investment manager founded in 1986 that specializes in real assets and alternative income, including listed real estate (REITs), infrastructure, preferred securities, and multi-strategy real assets. Xenon Pharmaceuticals is a Burnaby, Canada based, US-listed neuroscience biotech developing treatments for epilepsy and neuropsychiatric conditions. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.

Is CNS or XENE the better stock?

+

Neither is universally better; they suit different views and risk levels. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.

Which is cheaper, CNS or XENE?

+

A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.

Should you own both CNS and XENE?

+

Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.

What are the risks of CNS vs XENE?

+

CNS: CNS revenue is almost entirely tied to AUM, so equity or bond market drawdowns directly cut fees and earnings. Its concentration in real estate and rate-sensitive income means a reversal to higher-for-longer rates, or a rotation away from REITs and preferreds, could trigger outflows and market depreciation at the same time; the AUM declines reported for August and September 2026 show that dynamic at work. EPS has come in a cent or a few cents below consensus in three of the last four quarters, and October 2026 brought net outflows of about $209 million. The dividend absorbs about 81% of trailing earnings, which leaves less cushion if profits dip. The active-management fee model faces secular pressure from low-cost passive and index products, and net flows can turn negative in stressed markets. Newer private and non-traded initiatives add execution and liquidity risk, and results can be lumpy quarter to quarter. XENE: Xenon has no approved product and no meaningful revenue, so the entire valuation rests on azetukalner clearing FDA review and selling once launched. Clinical-stage biotech carries binary risk: a review delay, a complete response letter, or disappointing data in the generalized seizure or neuropsychiatric programs could sharply reset the stock, and the September 2026 pause of two psychiatry trials over dizziness, somnolence and neuropsychiatric side effects shows how tolerability questions can spill onto the shares. Even with approval, azetukalner would enter a crowded antiseizure market with established generics and branded competitors, and a likely DEA scheduling step could delay launch. The company continues to post large net losses (about $110 million in Q3 2026), and while it has said its cash runway extends into 2029, further dilution is possible if programs expand or slip. The shares are volatile and sensitive to single data points: they fell about 38% in the three months to November 20, 2026, and traded between roughly $33.38 and $72.66 over the past 52 weeks.

Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell CNS or XENE; figures are approximate and dated (as of November 2026). Verify current data before investing.